Book a discovery call

“Why is my waist growing, and does fixing it mean medication?”

Field Notes · By Chandni Menda, founder of Yellow · Last updated 8 November 2026

“Why is my waist growing, and does fixing it mean medication?”

The short answer: in the years around menopause, fat moves to the belly while muscle falls, so the waist can grow while the scale barely moves. Ageing drives most of the weight gain itself. India's menopause guideline starts with lifestyle change. It brings weight-loss injections in at a BMI of 27 or above, after six months of lifestyle change hasn't taken off 5%, and it asks for resistance training and protein alongside them. In India only endocrinologists and internal medicine specialists can prescribe them, and cardiologists for some uses.

A woman we spoke to in Mumbai told us her waist has been growing for a while. She eats the same food and has done the same yoga for ten years. She has given away four bundles of clothes.

So why is it happening now? And does fixing it mean medication?

Why the belly, when the scale barely moves?

SWAN followed women in the US through the menopause transition with body scans. Fat went up about 1% a year before the transition and 1.7% a year during it, while muscle went down. Across the three and a half years of the transition, the average woman put on about 1.6 kg of fat and lost about 0.2 kg of muscle.

Weight kept rising at the same rate as before, about a quarter of a kilo a year. So the scale showed little change while the mix of fat and muscle changed.

The change started about two years before the last period.

A smaller study followed 156 women for four years. Every one of them gained fat under the skin of the belly. Only the women who reached menopause gained the deep fat around the organs.

In India's national family health survey, which stops at 49, 40% of women had a waist above the cut-off for abdominal obesity. Only 23% had a BMI of 25 or above, India's line for obesity. So a woman can have a normal BMI and a large waist.

Is my metabolism broken?

A study that pooled energy measurements from 6,421 people found that, once you account for how much muscle and organ tissue a person has, daily energy use stays flat from 20 to about 60. It only starts falling after that.

Two details matter here. Resting energy use, in the same data, started falling earlier, around 46, though the estimate is wide. And a woman losing muscle through the transition burns less in absolute terms, even if the adjusted number stays flat.

Sleep matters too. In short lab studies, people who slept less ate about 385 extra calories a day, and burned no more. The studies were in adults in general.

India's menopause guideline, rewritten by the Indian Menopause Society this February, puts weight gain through the transition at about 0.7 kg a year. It says falling oestrogen changes where the fat goes, and that ageing is the main factor in the gain itself. More on what falling oestrogen does in our guide to low estrogen symptoms.

I also went looking for proof that stress hormones cause the menopause belly. I didn't find it. Our cortisol test guide explains what that test can and can't show.

Will HRT help the belly, or make it worse?

It doesn't seem to make it worse. A Cochrane review of randomised trials found hormone therapy made no difference to body weight. That review's search stopped in 1998, so it doesn't cover the newer patches and gels.

It may help a little. Across 107 trials up to 2004, hormone therapy cut abdominal fat by about 7% and insulin resistance by about 13% in women without diabetes. In the Women's Health Initiative, three years of combined hormone therapy almost stopped muscle loss. By year six, that difference had gone. Fat mass didn't change compared with placebo.

Those women averaged 63, more than a decade past menopause. The women writing to us are 38 to 50.

Hormone therapy isn't a weight-loss treatment, and no guideline I read treats it as one. A Spanish menopause society statement says the early finding that hormone therapy boosts weight loss on injections isn't strong enough to start it for that reason.

Do the injections work?

In trials, yes.

The people in those trials started at an average BMI of about 38. The manufacturers paid for the trials. In a Delhi clinic, looking back at 150 people on these drugs, the median loss was 8.2% over six months.

Most people get stomach side effects. In the semaglutide trial, 44% had nausea and a quarter vomited. India's Ministry of Health has named pancreatitis and medullary thyroid cancer as serious risks in its statements on these drugs.

What happens when you stop?

A year after stopping semaglutide, people had put back about two-thirds of what they lost. In the tirzepatide follow-up, people who switched to placebo regained 14% from the weight they had reached. People who stayed on kept losing.

Some of the weight lost is muscle. Across trials, a quarter to over a third of the weight lost on these drugs was lean mass. In one review of 20 trials, dieting without the drugs lost about the same share, and dieting plus resistance training lost less, about 17.5%. Another review, which took only studies where people lost at least 10% of their weight, found the drugs lost a larger share than diet and exercise. The share lost as lean mass tends to follow how much weight is lost.

Whether that muscle loss makes women weaker hasn't been measured: none of the 35 studies in one review reported an objective test of physical function.

Who decides, in India?

India's menopause guideline says medication comes in at a BMI of 27 or above, after six months of intensive lifestyle change hasn't brought weight down by 5%. GLP-1 drugs are the first choice, at the guideline's strongest grade, and orlistat and two others are second line. The guideline doesn't count metformin as an anti-obesity drug, and recommends it only for insulin resistance, prediabetes or PCOS.

India uses lower cut-offs than most charts. The guideline calls a BMI of 23 to 24.9 overweight and above 25 obese. India's 2025 obesity definition uses the same numbers and a different word: above 23 is stage 1 obesity. For the waist, India's menopause guideline sets two lines for women: above 72 cm, avoid gaining weight or lose some; above 80 cm, supervised weight management.

When these drugs were approved here, the Ministry of Health made it a condition that endocrinologists and internal medicine specialists prescribe them, and cardiologists for some uses. They can't be bought over the counter. Gynaecologists aren't on that list. Our guide on which doctor to consult covers who to see first.

After a price cut on 1 April 2026, branded semaglutide was listed at about Rs 5,660 to Rs 16,400 a month, depending on the dose. Generic semaglutide arrived in March 2026, at a wide range of prices. Some of the generics are approved only for diabetes.

What helps that isn't a drug?

The muscle figures are why I looked at this next. Of everyone losing weight across those trials, the people who lost the smallest share as muscle were the ones doing resistance training.

India's guideline asks for progressive resistance training, with protein at 1.0 to 1.5 g for every kilo of body weight a day, to keep muscle. For a woman who weighs 60 kg, that's 60 to 90 g of protein a day. Across 23 trials in postmenopausal women, combining strength work with cardio improved body composition and metabolic health. The effects were small.

Exercise on its own slows weight gain a little. In 3,064 American women followed for three years, each step up in how much sport and exercise they reported meant 0.32 kg less weight gained.

In 5,761 adults with body scans, more alcohol went with more deep belly fat, whatever their total fat. The study shows a link and can't show cause.

Can a supplement do this?

So, does fixing it mean medication?

For some women the guideline says yes, and it sets conditions: six months of lifestyle change first, a prescription from an endocrinologist or internal medicine specialist, and resistance training alongside. What happens when you stop is a question worth settling with that doctor before you start, because the trials show most of the weight returns.

The belly changes start about two years before the last period, and India's guideline starts with lifestyle change, before any prescription. If you're 40 or over, our guide to blood tests for women over 40 covers the basic checks a doctor may start with.

If you've been offered one of these drugs in your forties, what were you told about muscle, and about stopping? Write to me at hello@spotyellow.com.

Sources

  1. Greendale GA et al. Changes in body composition and weight during the menopause transition (SWAN). JCI Insight 2019.
  2. Lovejoy JC et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes 2008.
  3. Chaudhary M, Sharma P. Abdominal obesity in India: analysis of NFHS-5 data. Lancet Reg Health Southeast Asia 2023.
  4. Pontzer H et al. Daily energy expenditure through the human life course. Science 2021.
  5. Al Khatib HK et al. The effects of partial sleep deprivation on energy balance. Eur J Clin Nutr 2017.
  6. Meeta M et al. Clinical Practice Guidelines for Menopause: Executive Summary, Indian Menopause Society 2026. J Midlife Health 2026.
  7. Norman RJ et al. HRT and weight and body fat distribution. Cochrane Database Syst Rev 2000.
  8. Salpeter SR et al. Meta-analysis: HRT and components of the metabolic syndrome. Diabetes Obes Metab 2006.
  9. Chen Z et al. Women's Health Initiative body composition, 3 years. Am J Clin Nutr 2005.
  10. Bea JW et al. Women's Health Initiative body composition, 6 years. Menopause 2011.
  11. Sánchez-Prieto M et al. Incretin-based therapies in peri- and postmenopausal women with obesity: Spanish Menopause Society position statement. Maturitas 2026.
  12. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021. Manufacturer funded.
  13. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022. Manufacturer funded.
  14. Tchang BG et al. Body weight reduction in women treated with tirzepatide by reproductive stage. Obesity 2025. Manufacturer funded.
  15. Jarso G et al. Weight loss response to GLP-1/GIP receptor agonists in India: a real-world analysis. Indian J Endocrinol Metab 2026.
  16. Wilding JPH et al. Weight regain after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab 2022. Manufacturer funded.
  17. Aronne LJ et al. Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA 2024. Manufacturer funded.
  18. Eisa N, Barood O. Lean mass changes with incretin therapy versus lifestyle intervention. Diabetes Obes Metab 2026.
  19. Busk-Cirera L et al. Meta-analysis of lean mass loss with incretin drugs and diet. Diabetes Obes Metab 2026.
  20. Batsis JA et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med 2026.
  21. Misra A et al. Revised definition of obesity in Asian Indians living in India. Diabetes Metab Syndr 2025. The lead author discloses fees from manufacturers of these drugs and is the journal's editor.
  22. Ministry of Health and Family Welfare. Press release on GLP-1 prescribing, 24 March 2026, and PIB explainer, 1 April 2026.
  23. Novo Nordisk India price release, 31 March 2026, as reported by BioSpectrum, and PharmEasy listing, read November 2026.
  24. Liu C et al. Effects of concurrent training in postmenopausal women: a meta-analysis. BMC Womens Health 2026.
  25. Sternfeld B et al. Physical activity and changes in weight and waist circumference in midlife women (SWAN). Am J Epidemiol 2004.
  26. Chesters J et al. Greater visceral fat mass accumulation with high alcohol consumption. Int J Obes 2026.
  27. Elahi Vahed I et al. The effect of berberine on obesity indices. Int J Obes 2025.
  28. Amini MR et al. Meta-analysis of berberine and weight. Complement Ther Med 2020.
  29. Asbaghi O et al. Meta-analysis of berberine and obesity indices. Clin Nutr ESPEN 2020.
  30. Guo Y et al. Study of berberine and drug-metabolising enzymes. Eur J Clin Pharmacol 2012.
  31. Abou-Khalil R et al. Apple cider vinegar for weight management. BMJ Nutr Prev Health 2024. Retracted 23 September 2025.